AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $18.6667.

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. Canaccord Genuity Group decreased their price objective on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Monday, April 6th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Finally, Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently bought and sold shares of the business. Franklin Resources Inc. increased its holdings in AngioDynamics by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock worth $621,000 after buying an additional 1,076 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares in the last quarter. State of Wyoming increased its holdings in AngioDynamics by 53.6% in the 3rd quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 1,658 shares in the last quarter. Deutsche Bank AG increased its holdings in AngioDynamics by 5.9% in the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after buying an additional 1,992 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in AngioDynamics in the 4th quarter worth about $27,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Price Performance

AngioDynamics stock opened at $10.77 on Monday. The company has a market capitalization of $445.02 million, a P/E ratio of -14.36 and a beta of 0.37. The stock’s 50 day moving average is $10.75 and its 200 day moving average is $11.43. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $13.99.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $78.42 million for the quarter, compared to analysts’ expectations of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. As a group, equities analysts expect that AngioDynamics will post -0.19 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.